Fundraising Fox

ENDRA Life Sciences

NASDAQ: NDRA

Ann Arbor, US · Delaware corporation

Biotech

Founders & leadership

RJ
Richard JacrouxExecutive
FR
Francois R. MichelonExecutive
DW
David WellsExecutive
MT
Michael ThorntonNamed on SEC filing

Board

AD
Anthony DiGiandomenicoBoard director
LJ
Louis J. BaseneseBoard director
MH
Michael HarshBoard director
AT
Alexander TokmanBoard director
SS
Sanjiv S. GambhirBoard director

Reported raises · per SEC filings

Form D private placements

$26.8M disclosed across 4 rounds · 2018–2025

▶$14.4MraisedOct 2025 · 6 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Michael ThorntonExecutive Officer
  • Richard JacrouxExecutive Officer
  • Louis J. BaseneseDirector
  • Anthony DiGiandomenicoDirector
  • Michael HarshDirector
  • Alexander TokmanExecutive Officer, Director
Offering amount
$14.4M
Amount sold
$14.4M
Minimum investment
$200K
Sales commissions
$295.5K
Placement agents
Lucid Capital Markets, LLC
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$8.6MraisedDec 2019 · 151 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexander TokmanDirector
  • Michael HarshDirector
  • Anthony DiGiandomenicoDirector
  • Sanjiv S. GambhirDirector
  • David WellsExecutive Officer
  • Michael ThorntonExecutive Officer
  • Francois R. MichelonExecutive Officer, Director
Offering amount
$8.6M
Amount sold
$8.6M
Minimum investment
$5K
Sales commissions
$766.2K
Placement agents
Newbridge Securities Corporation
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJul 2019 · 86 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael HarshDirector
  • David WellsExecutive Officer
  • Francois R. MichelonExecutive Officer, Director
  • Michael ThorntonExecutive Officer
  • Alexander Y. TokmanDirector
  • Sanjiv S. GambhirDirector
  • Anthony DiGiandomenicoDirector
Offering amount
$2.8M
Amount sold
$2.8M
Minimum investment
$20K
Sales commissions
$280.5K
Placement agents
National Securities Corporation
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedJul 2018 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Francois R. MichelonExecutive Officer, Director
  • Michael HarshDirector
  • Sanjiv S. GambhirDirector
  • David WellsExecutive Officer
  • Michael ThorntonExecutive Officer
  • Anthony DiGiandomenicoDirector
  • Alexander Y. TokmanDirector
Offering amount
$1.1M
Amount sold
$1.1M
Minimum investment
$50K
Sales commissions
$107.7K
Placement agents
National Securities Corporation
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

ENDRA Life Sciences (NASDAQ: NDRA) raises $3.8M to bolster equity for Nasdaqstocktitan.net · May 2026ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Resultsfinance.yahoo.com · Nov 2025US-listed company ENDRA Life Sciences raises approximately $4.9 million to launch a Digital Asset Treasury (DAT) strategy | WEEX Crypto Newsweex.com · Oct 2025ENDRA Life Sciences raises $4.9 million, launches crypto strategy By Investing.comau.investing.com · Oct 2025NDRA Stock | ENDRA Life Sciences Inc Price, Quote, News & Analysis - TipRanks.comtipranks.com

Frequently asked questions

How much funding has ENDRA Life Sciences raised?
ENDRA Life Sciences has disclosed $26.8M raised across 4 rounds.
Where is ENDRA Life Sciences headquartered?
ENDRA Life Sciences is headquartered in Ann Arbor, US.